

Management Participation in a Sale of Life Science Business Transaction

By Martin Florman, Daniel S. Dubyak, Chris M. Kang | October 22, 2026

RELATED PRACTICES Employee Benefits and Executive Compensation, Healthcare and Life Sciences, Life Sciences, Tax, Mergers and Acquisitions, Corporate

Management financial participation can be a critical issue when a life science business enters a sale of business transaction. Bonuses and equity arrangements can affect deal economics, retention and the value of the company's scientific and regulatory talent, making early, focused guidance essential. The right approach depends on the details of the business and transaction, and experienced counsel can help identify the issues before they become obstacles.

Bonuses

1. **Discretionary Bonuses.** Discretionary bonuses can recognize the contributions of scientific, R&D and executive leaders who help drive a life science transaction, even when no fixed payment is promised. However, these awards can raise governance, diligence and unexpected cost concerns.
2. **Change of Control Bonuses.** Contractual change of control bonuses can provide a meaningful retention tool for officers who hold critical knowledge of a life science company's pipeline, regulatory strategy and intellectual property. Their triggers, scope and aggregate cost can materially shape the transaction, so the arrangements should be reviewed early and aligned with the proposed deal structure.

Equity

3. **Stock Options.** Stock options are often central to officer compensation at emerging biotech and life science companies, but a sale can change vesting, exercise or payout in ways that materially affect both officers and the deal. Careful review of the plan and transaction documents is essential to protect intended economics and avoid surprises.
4. **Restricted Stock.** Restricted stock awards may be tied to service, regulatory milestones, clinical progress or commercial goals that are especially important in a life science business. A sale can accelerate, preserve or cancel those awards, making the treatment of each grant a key diligence and retention issue.
5. **Restricted Stock Units (RSUs).** RSUs can be settled, assumed or accelerated in a sale, and the answer may depend on how the plan, award and transaction documents fit together. Life science deals involving earnouts or other contingent consideration can add further complexity, so early review helps avoid unexpected costs and preserve key talent.
6. **Profits Interests in a Limited Liability Company.** For life science businesses organized as LLCs, profits interests can give officers a meaningful share in future value and help attract and retain talent. Their treatment in a sale depends heavily on the operating agreement and related awards, making these arrangements an important focus of transaction planning.

Equity Alternatives

7. **Phantom Stock.** Phantom stock can mirror the economics of actual equity without diluting ownership. Life science companies may use it to incentivize key talent tied to transaction value, but the specific plan terms and deal structure determine how these awards are treated in a sale.
8. **Stock Appreciation Rights (SARs).** SARs let officers capture the upside of a company's growth without requiring an outright stock purchase. In a life science company, the settlement method and triggers can vary significantly based on the plan and transaction terms, so careful structuring helps ensure these rights deliver their intended benefit.

Vesting

9. **Vesting Implications.** A sale can alter vesting schedules across the full range of equity and quasi-equity awards. Whether awards accelerate, forfeit or convert may hinge on specific plan language and deal structure. Therefore, understanding these implications early is key to protecting value for both the company and its officers.

Tax

10. **Tax Implications.** The tax treatment of bonuses and equity participation can materially affect the officer's net benefit and the company's transaction costs, particularly where life science packages include significant equity or milestone-based payments. Given that the analysis is highly fact-specific, early advice can help identify planning opportunities and avoid costly surprises.

For life science business owners, management participation arrangements can influence deal value, retention and the successful transfer of scientific and regulatory know-how. These issues are interconnected and highly fact-specific, making expert guidance an important part of the transaction process from the outset. We invite life science companies and their executives to [contact us](#) to discuss how to approach these issues with confidence.